Biomolecules bound to the sensor surface form a biofilm that causes interference phenomena to the light waves passing through the sensor. The interference phenomenon is detected in the form of a phase shift, allowing the detection of changes in the number of molecules bound to the sensor surface. CD BioSciences provides professional BLI technology for drug screening to help customers complete biofilm related research.
Single concentration compound library screening
Experimental validation of the concentration gradient of seedling compounds
Multi-target affinity selective single-concentration screening
Compound affinity determination for active proteins
Buffer: PBS, HEPPS, etc. without organic reagents, without Tris
Protein sample (with antibody): 200 ug, concentration >0.5 mg/ml
Peptide sample: 200 ug, concentration>1mg/ml
Compound small molecule: 200 ug, concentration>1 mg/ml
Please inform us of your specific BLI technology for drug screening details, and we can provide customized solutions for different projects.
CD BioSciences is a professional biofilm technology provider, supporting a variety of BLI technology for drug screening service. We can perform individual tests at the most precise level, as well as design and complete a suite of services as a solution to the subject project. CD BioSciences has many years of experience in BLI technology for drug screening serviceand has been a trusted partner to our clients for a long time. Please feel free to contact us for more detailed information, our scientists will tailor the most reasonable plan for your project.
CD BioSciences is a specialized company providing biofilm services with expertise in the intersection of chemistry and biophysics. Our platform offers advanced technologies to meet all your biofilm needs.
Copyright © CD BioSciences. All Rights Reserved.